Literature DB >> 3366131

Tumoral calcinosis revisited--common and uncommon features. Report of ten cases and review.

A Metzker1, B Eisenstein, J Oren, R Samuel.   

Abstract

Familial cutaneous and subcutaneous tumoral calcifications are a recognized entity of unknown pathogenesis. The course of calcinosis and various treatments are discussed and the literature concerning the aetiology is reviewed. Our ten cases provided some experience in dealing with tumoral calcinosis and demonstrated, in addition, some clinical phenomena unrecognized previously, such as involvement of the mucous membranes and an erythematous rash preceding the development of calcified nodules.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3366131     DOI： 10.1007/bf00442209

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  22 in total

1.  Treatment of tumoral calcinosis with phosphorus deprivation.

Authors:  G Mozaffarian; F W Lafferty; O H Pearson
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

2.  Diphosphonate treatment of calcinosis universalis.

Authors:  R L Cram; R Barmada; W B Geho; R D Ray
Journal:  N Engl J Med       Date:  1971-10-28       Impact factor: 91.245

3.  Tumoral calcinosis and pseudoxanthoma elasticum.

Authors:  S S Najjar; F S Farah; A K Kurban; R E Melhem; A K Khatchadourian
Journal:  J Pediatr       Date:  1968-02       Impact factor: 4.406

4.  Cortical hyperostosis with hyperphosphatemia: a new syndrome?

Authors:  R E Melhem; S S Najjar; A K Khachadurian
Journal:  J Pediatr       Date:  1970-12       Impact factor: 4.406

5.  Tumoral calcinosis with hyperphosphatemia. A report of a family with incidence in four siblings.

Authors:  H Baldursson; E B Evans; W F Dodge; W T Jackson
Journal:  J Bone Joint Surg Am       Date:  1969-07       Impact factor: 5.284

6.  Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma.

Authors:  A L Metzger; F R Singer; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1974-12-12       Impact factor: 91.245

7.  Calcium and phosphate metabolism in tumoral calcinosis.

Authors:  P D Mitnick; S Goldfarb; E Slatopolsky; J Lemann; R W Gray; Z S Agus
Journal:  Ann Intern Med       Date:  1980-04       Impact factor: 25.391

8.  Tumoral calcinosis.

Authors:  G G Smit; A Schmaman
Journal:  J Bone Joint Surg Br       Date:  1967-11

9.  Tumoral calcinosis--an unrecognized disease.

Authors:  S McClatchie; A D Bremner
Journal:  Br Med J       Date:  1969-01-18

10.  Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling.

Authors:  H Stark; B Eisenstein; M Tieder; A Rachmel; G Alpert
Journal:  Nephron       Date:  1986       Impact factor: 2.847
View more
  22 in total

1.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.

Authors:  Ilana Chefetz; Raoul Heller; Assimina Galli-Tsinopoulou; Gabriele Richard; Bernd Wollnik; Margarita Indelman; Friederike Koerber; Orit Topaz; Reuven Bergman; Eli Sprecher; Eckhard Schoenau
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

Review 2.  Familial tumoral calcinosis: a valuable vehicle for discovery.

Authors:  Orson W Moe
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

3.  Vitamin D metabolism in tumoral calcinosis.

Authors:  R Steinherz
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

4.  Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.

Authors:  M F Campagnoli; A Pucci; E Garelli; A Carando; C Defilippi; R Lala; G Ingrosso; I Dianzani; M Forni; U Ramenghi
Journal:  J Clin Pathol       Date:  2006-04       Impact factor: 3.411

Review 5.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

6.  A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis.

Authors:  Orit Topaz; Margarita Indelman; Ilana Chefetz; Dan Geiger; Aryeh Metzker; Yoram Altschuler; Mordechai Choder; Dani Bercovich; Jouni Uitto; Reuven Bergman; Gabriele Richard; Eli Sprecher
Journal:  Am J Hum Genet       Date:  2006-08-24       Impact factor: 11.025

7.  Calcinosis cutis, osteoma cutis, poikiloderma and skeletal abnormalities (COPS syndrome)--a new entity?

Authors:  A P Oranje; S M de Muinck Keizer-Schrama; V D Vuzevski; M Meradji
Journal:  Eur J Pediatr       Date:  1991-03       Impact factor: 3.183

8.  Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.

Authors:  Eli Sprecher
Journal:  J Invest Dermatol       Date:  2009-10-29       Impact factor: 8.551

9.  Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein.

Authors:  Ilana Chefetz; Danny Ben Amitai; Sarah Browning; Karl Skorecki; Noam Adir; Mark G Thomas; Larissa Kogleck; Orit Topaz; Margarita Indelman; Jouni Uitto; Gabriele Richard; Neil Bradman; Eli Sprecher
Journal:  J Invest Dermatol       Date:  2007-12-20       Impact factor: 8.551

10.  Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome.

Authors:  Faysal Gok; Ilana Chefetz; Margarita Indelman; Murat Kocaoglu; Eli Sprecher
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.